Navigation Links
Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Release of Study Finding Tylenol Use in Pregnancy May Affect Child Development
Date:12/19/2013

New York, NY (PRWEB) December 19, 2013

As Tylenol lawsuits (http://www.tylenollawsuitclaims.com/) continue to mount in courts around the country, Bernstein Liebhard LLP notes that a newly published study has reported a possible association between the use of acetaminophen in pregnancy and problems with child development. Acetaminophen is the active ingredient in Tylenol-brand over-the-counter medications.

The study, which was published online in the International Journal of Epidemiology, looked at 8,000 Norwegian children whose mothers were surveyed about their medication use at weeks 17 and 30 of pregnancy. They were also surveyed at 6 months post-partum, and were asked to complete a follow-up questionnaire about their child's developmental milestones three years later. The children of women who reported the most frequent acetaminophen use (at least 28 days during pregnancy) appeared to exhibit poorer motor, language and communication skills than other children. They also had more behavior problems, according to the authors of the study.*

“While the lawsuits we are investigating involve allegations that Tylenol can cause severe liver damage, this study serves to remind that acetaminophen may carry some very real risks,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free legal reviews to individuals who may have suffered liver damage associated with the use of Tylenol.

Tylenol and Liver Damage
According to the U.S. Food & Drug Administration (FDA), acetaminophen was the leading cause of acute liver failure in the U.S. between 1998 and 2003. From 1990 to 1998, acetaminophen was blamed for 56,000 emergency room visits, 26,000 hospitalizations, and 458 deaths annually.

According to court documents, at least 100 Tylenol lawsuits involving liver damage allegations are now pending in a federal multidistrict litigation underway in U.S. District Court, Eastern District of Pennsylvania. All of the lawsuits allege that Tylenol products can cause liver damage, even when taken as directed. The lawsuits further allege that many victims of Tylenol liver damage were hospitalized, required a liver transplant, or died, as a result of acetaminophen in the over-the-counter medications. (In Re: Tylenol (Acetaminophen) Marketing, Sales Practices and Products Liability Litigation, MDL No. 2436)

This past summer, Johnson & Johnson announced it was adding more prominent, red-lettered warnings to the labels of Tylenol products regarding the potential for sever liver damage. According to a report from Bloomberg.com, Extra Strength Tylenol – which contains 500 milligrams of acetaminophen per tablet - was to appear with the warnings in October. Other products will bear the warnings in the coming months.**

Individuals who suffered acetaminophen-induced liver damage resulting in hospitalization, liver transplantation or death allegedly associated with a Tylenol product may be entitled to compensation for medical expenses and other injury-related damages. Find out more about filing a Tylenol lawsuit by visiting Bernstein Liebhard LLP’s website. For a free evaluation of your claim, please call 800-511-5092.

*ije.oxfordjournals.org/content/early/2013/10/24/ije.dyt183.abstract, Journal of Epidemiology, October 2013
**bloomberg.com/news/2013-08-29/j-j-adds-warning-to-tylenol-caps-on-acetaminophen-risk.html, Bloomberg.com, August 29, 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.tylenollawsuitclaims.com/
https://plus.google.com/115936073311125306742?rel=author

Read the full story at http://www.prweb.com/releases/tylenol-lawsuit/tylenol-liver-damage/prweb11438415.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Tylenol Liver Problem Allegations Help: Resource4thePeople Comments on Legal Developments
2. Tylenol Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Tylenol Litigation
3. Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Filing of New Claim Alleging Use of Tylenol Caused Liver Damage
4. Tylenol Liver Damage Allegations Lawyer Help: Resource4thePeople Reports Judge Outlines Procedures for Bellwether Trials
5. Injury Law Firm Comments on the FDA Consumer Update Warning about Tylenol Side Effects like SJS
6. Tylenol Lawsuit News: New Jersey Supreme Court Refuses Multicounty Case Consolidation, Rottenstein Law Group LLP Reports
7. Latest Tylenol Liver Failure Lawsuit Allegations Report: Resource4thePeople Urges Consumers to Fully Inform Themselves about Liver Disease Danger Possibility
8. Rottenstein Law Group LLP Announces New Tylenol Lawsuit Center
9. Update on Alleged Tylenol Liver Failure Lawsuits from Resource4thePeople: Judge Selects Steering Committee in Multidistrict Litigation
10. Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center
11. Anxious about life? Tylenol may do the trick
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... and clinical outcomes, hosted members and suppliers for its inaugural Member Conference at ... on their mission of elevating the operational health of America’s healthcare providers. , ...
(Date:5/26/2016)... ... ... Connor Sports, through its Connor Cares initiative, will continue to ... Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and final ... and levels of the game, Connor Sports has committed to a significantly increased focus ...
(Date:5/26/2016)... Pompano Beach, Florida (PRWEB) , ... May 26, 2016 , ... ... Green House® Project offering a new model of care for living and ... on three core values: Meaningful Life in a Real Home provided by Empowered Staff. ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are nearly 14.5 ... 32 million cancer survivors worldwide. On Sunday, June 5, 2016, communities around the world ... Cancer Survivors Day®. , National Cancer Survivors Day® is an annual worldwide Celebration ...
(Date:5/26/2016)... ... 26, 2016 , ... Catalent Pharma Solutions, the leading global ... and global clinical supply services, today announced two key appointments and the opening ... and strategic growth plans in the Asia Pacific region. , Howard Kim has ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... -- MedDay, a biotechnology company focused on the ... entitled "High doses of biotin in progressive multiple sclerosis: extension ... Professor Ayman Tourbah , Principal Investigator of the Phase ... of Neurology (EAN) in Copenhagen, Denmark . ... place on Sunday, 29 May 2016 from 14:45 to 16:15 ...
(Date:5/24/2016)... 2016 Niederländische Chirurgen haben ... es Ärzten erlaubt, ihre Expertise weltweit zu teilen ... Live Streaming mit einer Instant-Messaging-Funktion und der Möglichkeit, ... in Europa, Afrika, Asien und den ... Plattform registriert. Information und Weiterbildung   ...
(Date:5/24/2016)...   , Study met both ... superiority in , Excellent plus Good ... of the ascending colon   , ... today announced new positive data from the phase III MORA study ... 2 litre PEG with ascorbate. The study met both primary endpoints ...
Breaking Medicine Technology: